(Total Views: 949)
Posted On: 03/12/2017 10:32:09 AM
Post# of 98292
![Avatar](https://investorshangout.com/images/ProfileImages/934136062_182_A_Dawgg 1 Two 10-baggers at the same time..jpg)
$RNN breakout candles $0.378
Above upper bollie
Amex
Website
Last ten trades
10-K 2/24/17
100% x 100% Strong Buy
Shares Outstanding 237.44M
Float 230.21M
% Held by Insiders 4.19%
% Held by Institutions 4.80%
Shares Short 3 2.31M
Short Ratio 0.72
Short % of Float 1.12%
Shares Short (prior month) 2.84M
Stock technical analysis
news
and filings
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companys clinical stage oncology candidates include Archexin that completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; RX-3117, which is in Phase Ib clinical trial for the treatment of patients with solid tumors; and Supinoxin that is in Phase I clinical trial for patients with solid tumors. It is also involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.
Above upper bollie
Amex
Website
Last ten trades
10-K 2/24/17
![1642481658_otc.jpeg](http://investorshangout.com/images/MYImages/1642481658_otc.jpeg)
100% x 100% Strong Buy
![850318709_barchart_logo1.jpg](http://investorshangout.com/images/MYImages/850318709_barchart_logo1.jpg)
Shares Outstanding 237.44M
Float 230.21M
% Held by Insiders 4.19%
% Held by Institutions 4.80%
Shares Short 3 2.31M
Short Ratio 0.72
Short % of Float 1.12%
Shares Short (prior month) 2.84M
Stock technical analysis
![895828223_stockta5.jpg](http://investorshangout.com/images/MYImages/895828223_stockta5.jpg)
news
and filings
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companys clinical stage oncology candidates include Archexin that completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; RX-3117, which is in Phase Ib clinical trial for the treatment of patients with solid tumors; and Supinoxin that is in Phase I clinical trial for patients with solid tumors. It is also involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
Scroll down for more posts ▼